The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
A 63-year-old man with type 2 diabetes, diabetic peripheral neuropathy, chronic kidney disease stage 3 (eGFR 42), and obesity (BMI 34) is referred by his endocrinologist for depressive symptoms. He reports 6 months of depressed mood, loss of interest, fatigue, poor concentration, feelings of hopelessness about his health, and hemoglobin A1c that has risen from 7.2% to 9.1% due to decreased medication adherence and dietary neglect. His PHQ-9 score is 18. He reports chronic bilateral foot pain from the neuropathy rated 6 out of 10 that significantly impacts his sleep and daily functioning. He is currently on metformin, lisinopril, and gabapentin 300 mg three times daily with partial pain relief. Which treatment plan best addresses the interconnected nature of his conditions?
Explanation
In patients with comorbid depression and diabetic neuropathy, duloxetine offers the advantage of dual FDA-approved indications, potentially simplifying the medication regimen. Behavioral activation with integrated health behavior change strategies addresses the depression and the diabetes self-management nonadherence simultaneously. Coordinating with the primary medical team ensures aligned treatment goals recognizing the bidirectional depression-diabetes relationship.
Key Takeaway
Duloxetine's dual efficacy for depression and diabetic neuropathy makes it the optimal pharmacotherapy choice for this comorbidity, combined with behavioral interventions targeting both depression and diabetes self-management within a coordinated care framework.